RRx-001 + irinotecan + temozolomide

**RRx-001 + irinotecan + temozolomide** is an investigational combination regimen involving three distinct agents: RRx-001, irinotecan, and temozolomide. - **RRx-001** is a cysteine-directed, hypoxia-activated small molecule with multiple mechanisms relevant to cancer therapy, including *NLRP3 inflammasome inhibition*, *macrophage polarization*, *CD47 antagonism*, *vascular normalization*, and *epigenetic modification*[1]. - **Irinotecan** is a well-established topoisomerase I inhibitor that prevents DNA unwinding, leading to apoptosis in cancer cells. - **Temozolomide** is an oral alkylating agent that methylates DNA, inducing cell death in tumor cells. This combination is designed to exploit the chemosensitizing effects of RRx-001, resensitizing tumors to chemotherapy agents like irinotecan and temozolomide, typically in cases of treatment-resistant cancers[1]. Clinical trials have explored RRx-001 in combination strategies, often aiming to overcome acquired resistance and improve efficacy.

Brand names

None found for the specific triple combination

Other names

None found for the specific triple combination